NetworkNewsBreaks – Aegis Reiterates ‘Buy’ Rating for Xtant Medical Holdings, Inc. (NYSE: XTNT) following 2016 Preliminary Results, Guidance for 2017

Noting two quarters of double-digit growth, Aegis Capital has reiterated its ‘Buy’ rating and $3.50 price target for Xtant Medical (NYSE MKT: XTNT). Xtant Friday reported preliminary fourth quarter 2016 revenues of at least $24.5 million, an increase of 10% compared to the year ago quarter, and in line with Aegis estimates of $24.6 million. Adjusted EBITDA for the fourth quarter is expected to be at least $1.25 million vs a loss of $350,000 in the fourth quarter of 2015, shy of Aegis’ estimates of $1.5 million. Xtant estimates full-year 2016 revenue of at least $90 million, up 4.1% compared to full-year 2015, and in line with Aegis estimates; and full year Adjusted EBITDA of at least $2.2 million versus a pro forma loss of $33,000 for full year 2015. Xtant also reaffirmed its guidance for full-year 2017 revenues between $98 million-$102 million with Adjusted EBITDA guidance of between $7.7 million and $9.2 million, both in line with Aegis estimates.

To view the full press release, visit:

About Xtant Medical Holdings

Xtant Medical Holdings, Inc. (NYSE MKT: XTNT) develops, manufactures and markets class-leading regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. With core competencies in both biologic and non-biologic surgical technologies, Xtant can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. For further information, please visit

About NetworkNewsBreak

NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, visit

Please see full disclaimers on the NetworkNewsWire website:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s